Objective: Seizures develop in 80% of patients with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, and these represent a major cause of morbidity and mortality. Anti-NMDAR antibodies have been linked to memory loss in encephalitis; however, their role in seizures has not been established. We determined whether anti-NMDAR antibodies from autoimmune encephalitis patients are pathogenic for seizures. Methods: We performed continuous intracerebroventricular infusion of cerebrospinal fluid (CSF) or purified immunoglobulin (IgG) from the CSF of patients with anti-NMDAR encephalitis or polyclonal rabbit anti-NMDAR IgG, in male C57BL/6 mice. Seizure status during a 2-week treatment was assessed with videoelectroencephalography. We assessed memory, anxiety-related behavior, and motor function at the end of treatment and assessed the extent of neuronal damage and gliosis in the CA1 region of hippocampus. We also performed whole-cell patch recordings from the CA1 pyramidal neurons in hippocampal slices of mice with seizures. Results: Prolonged exposure to rabbit anti-NMDAR IgG, patient CSF, or human IgG purified from the CSF of patients with encephalitis induced seizures in 33 of 36 mice. The median number of seizures recorded in 2 weeks was 13, 39, and 35 per mouse in these groups, respectively. We observed only 18 brief nonconvulsive seizures in 11 of 29 control mice (median seizure count of 0) infused with vehicle (n = 4), normal CSF obtained from patients with noninflammatory central nervous system (CNS) conditions (n = 12), polyclonal rabbit IgG (n = 7), albumin (n = 3), and normal human IgG (n = 3). We did not observe memory deficits, anxiety-related behavior, or motor impairment measured at 2 weeks in animals treated with CSF from affected patients or rabbit IgG. Furthermore, there was no evidence of hippocampal cell loss or astrocyte proliferation in the same mice. Significance: Our findings indicate that autoantibodies can induce seizures in anti-NMDAR encephalitis and offer a model for testing novel therapies for refractory autoimmune seizures.
| INTRODUCTION
Anti-NMDAR (N-methyl-D-aspartate receptor) encephalitis is a prevalent autoimmune encephalopathy that surpassed the incidence of viral encephalitis in the California encephalitis project. 1 The disease is characterized by confusion, psychosis, dysautonomia, as well as movement disorders, and is often associated with persistent seizures that require treatment with pharmacologically induced coma. 2, 3 New-onset seizures have been diagnosed in 78%-86% of patients with anti-NMDAR encephalitis 4, 5 and have been reported in all stages of the illness. 6 The spectrum of clinical presentation of seizures includes purely electrographic seizures, generalized convulsions, and focal seizures with loss of awareness. 7 Particularly, severe treatment-resistant seizures were initially reported in 6% of patients 4 ; however, a growing number of reports suggest that this number may have been grossly underestimated. [8] [9] [10] [11] [12] [13] [14] Thus, in the recent multicenter study of patients with anti-NMDAR encephalitis, 42% required intensive care unit settings and convulsive or nonconvulsive status epilepticus was present in 45% of these patients. Moreover, status epilepticus was deemed refractory to anticonvulsants in two-thirds of patients. 14 Although overall clinical improvement in nonparaneoplastic anti-NMDAR encephalitis occurs in <50% of patients following first-line immunotherapy, 15 seizures appear to respond well to conventional anticonvulsants in the majority of patients. 7 The presence of NMDAR antibodies associates with seizures, but their pathogenic role has not been established. 16 Infusion of anti-NMDAR antibodies in mice did not cause seizures unless their seizure threshold had been reduced by the chemical convulsant, pentylenetetrazol. 17 The reason for the unsuccessful attempts to reveal spontaneous seizures could be a short duration of treatment with antibodies, 17, 18 or that the seizures might have been exclusively electrographic and present without behavioral correlates. 19, 20 Therefore, in previous studies of mice infused with patients' cerebrospinal fluid (CSF) that is NMDAR-IgGpositive, nonconvulsive seizures may not have been detected because simultaneous electrographic monitoring was not performed. 21 The lack of an animal model of autoimmune epilepsy limits our understanding of the mechanisms of seizure production and hampers the development of new treatments for these patients. Recent in vitro studies showed that patients' antibodies caused reversible titer-dependent internalization of NMDAR synaptic clusters and decreased cell-surface receptor density. 22, 23 Furthermore, antibodies decreased synaptic NMDAR-mediated currents in cultured hippocampal neurons. 22, 23 In mouse hippocampal slices exposed to CSF positive for anti-NMDAR antibodies, impaired long-term potentiation (LTP) was observed. 24 In addition, short-term intracerebroventricular (icv) administration of patients' CSF to rats led to decreased excitatory postsynaptic potentials in hippocampal granule cells that was accompanied by the impairment of memory and learning. 18 Thus, the loss of NMDAR-mediated synaptic function, observed most prominently in the hippocampus in anti-NMDAR encephalitis, 22 could explain the cognitive impairment;
however, the question remains whether these effects are accompanied by spontaneous seizures.
In the present study, we assessed the role of anti-NMDAR antibodies in the development of autoimmune seizures in mice by administering continuously via icv route rabbit anti-NMDAR antibodies or CSF from affected patients and measuring seizure activity by electroencephalography (EEG). We also examined the behavioral phenotype of mice with antibody-induced seizures and assessed hippocampal pathology. The data in this study provide evidence that autoantibodies in NMDAR encephalitis are pathogenic for seizures. The mouse model of seizures in anti-NMDAR encephalitis characterized in these experiments can be used to assess novel therapies for this devastating acute-onset epilepsy, as well as provide a means to study other still cryptogenic epilepsies, such as new-onset refractory status epilepticus.
| METHODS
We used male C57BL/6 mice that were 8-10 weeks old at the time of electrode implantation. Experimental polyclonal antibodies against the N-terminal domain of human GluN1 protein 25 and experimental CSF specimens (provided by S.J.P.) were pooled from clinical residuals from 8 patients
Key Points
• CSF or purified IgG from patients with anti-NMDAR encephalitis, as well as polyclonal rabbit anti-NMDAR IgG antibodies, induced seizures in mice • Antibody-induced seizure timing did not demonstrate daily or diurnal fluctuations • Mice exposed to CSF or anti-NMDAR IgG antibodies from patients did not develop memory deficits and they did not show anxiety-related behavior or motor impairment • Excitability and membrane resistance of CA1 pyramidal neurons in mice hippocampal slices treated with patient CSF were reduced compared to those in control mice with anti-NMDAR encephalitis and high CSF antibody titer ( Figure S1 ) and one patient of O.T. with anti-NMDAR encephalitis and seizures. Control CSF pooled from 3 patients with noninflammatory diseases of the central nervous system had no detectable anti-NMDAR antibodies by both tissue-and cell-based indirect immunofluorescence. Purified patient antibodies in the immunoglobulin G (IgG) fraction of CSF (experimental) and normal serum human IgG (control) were purified from clinical residuals of patients with anti-NMDAR encephalitis and healthy volunteers, respectively (provided by S.J.P.). (See Data S1 for detailed descriptions of animals, drugs, and CSF specimens.)
| Stereotaxic surgery and osmotic minipump insertion
Mice were stereotactically implanted with injector guide cannula into the lateral ventricle, a head mount for 2 EEG/ 1 electromyography (EMG) channels (Pinnacle Technology Inc.) and 2 cortical screw EEG electrodes placed to record signals from the parietal cortex overlying hippocampus (EEG 1) and ipsilateral frontal cortex (EEG 2). After a 7-day recovery period, mice were implanted with osmotic minipumps filled with antibody solution, CSF, or vehicle; the pumps were connected to the guide cannula. Animals underwent continuous icv infusion of patients' CSF or rabbit anti-NMDA IgG or phosphate-buffered saline (PBS), polyclonal rabbit IgG or normal CSF (n = 4-9) for 2 weeks at a flow rate of 0.25 μL/h ( Figure 1) ; the latter 3 groups were combined into a single control group for analysis (surgical details in Data S1). A similar experimental paradigm was used to infuse purified patient anti-NMDAR antibodies in the IgG fraction of normal CSF, human albumin, and normal human serum IgG (n = 3 in each group).
| EEG acquisition and analysis of seizure patterns
The EEG system (Pinnacle 8206, Pinnacle Technology) comprised a preamplifier unit connected by a tether to a conditioning/acquisition system. Signals were sampled at 400 Hz (preamplifier gain at 100×, total gain 5000×, high pass EEG channel filter 0.5 Hz, low pass EEG filter 50 Hz), digitized using a 14-bit analog to digital converter, and routed to a PC (personal computer). EEG signals were categorized as normal or seizures (>5 seconds of sustained, rhythmic high-amplitude activity in both EEG leads). 26 Events separated by >10 seconds of baseline activity were defined as distinct events. Seizure behavior was assessed using a modified Racine scale 27 during seizure and 10 seconds thereafter; events attributed to extraneous motor movements generated by normal mouse behavior were ignored (details in Data S1).
| Behavioral assays
Upon completion of 2-week EEG recording, animals underwent assessment of memory, anxiety-related behavior, and motor function in novel object recognition, open field, and accelerated rotarod tests, respectively (Figure 1 ; details in Data S1).
| Histopathology
Upon completion of behavioral experiments, animals were sacrificed and brains were processed for immunochemistry glial fibrillary acidic protein (GFAP; astrocytes) and fluoroJade C (damaged neurons) as described previously. 28 Histologic quantification of these cells in hippocampi was performed using ImageJ (NIH).
To compare the gliosis in CSF-perfused mice with an epilepsy model known to result in gliosis, sections of brain from mice with pilocarpine-induced status epilepticus were processed as described in Data S1.
| Whole cell patch recordings in hippocampal slices
Hippocampal slice preparations and recordings paradigms were performed as described 29 (see Data S1 for details).
| Statistical analysis
Data for median seizure counts and total time in seizures were not normally distributed; therefore, the Kruskal-Wallis and Dunn tests with selected comparisons (or Mann-Whitney tests) were used (GraphPad Prism 7, GraphPad Software). Means (latency to the first seizure, the daily seizure burden scores, cognitive, and locomotor scores) were compared using analysis of variance (ANOVA). Diurnal seizure count fluctuations and total seizure counts during the light and dark cycles were compared by repeated measure ANOVA and t test, respectively. GFAP-positive cell counts were compared between vehicle and pilocarpine-treated mice using unpaired t test, and among the combined control, CSF-and rabbit IgG-treated mice using ANOVA. Data for the whole cell patch recordings in hippocampal slices were expressed as the mean ± standard error of the mean (SEM) and analyzed using paired t test (excitability) or Student unpaired t test (all other data). Differences with P < 0.05 were considered statistically significant. The median seizure duration, the interseizure intervals (ISIs) between successive seizures, and median ISI in mice treated with human CSF were calculated with Microsoft Excel (Microsoft); a distribution function of number of seizures and intervals was generated and plotted with Origin (OriginLab). The ISI was compared to ISI of 190 minutes (expected if seizures occurred evenly throughout the 2-week recording period) with one-sample t test. The diurnal seizure count variations were assessed with repeatedmeasure ANOVA, whereas the total seizure counts during the light and dark cycles were compared using t test. The sample size was estimated based on the previously published studies using comparable experimental protocols. 21 EEG tracings generated at the University of Nebraska Medical Center (UNMC) are available from the corresponding author on request.
| RESULTS

| CSF from patients with anti-NMDAR encephalitis induces seizures in mice
We infused purified rabbit anti-NMDAR IgG (0.2 μg/μL) continuously into the lateral ventricles of mice for 14 days and found that prolonged exposure to antibodies induced seizures in 10 of 11 animals ( Figure 2A ; P < 0.001 Kruskal-Wallis test; P = 0.006, Dunn multiple comparisons tests vs combined control). Using the same experimental conditions, we performed a passive transfer of CSF from a single patient or high titer pooled CSF of patients with anti-NMDAR encephalitis. Consistent with the effects of anti-NMDAR IgGs, CSF from affected patients induced seizures in 16 of 17 mice ( Figure 2A ; P < 0.0001, Dunn multiple comparisons test). The variability in seizure counts in mice is expected from the clinical seizure phenotype in patients who demonstrate wide variability in seizure burden. Data from the corresponding control groups, which included vehicle (n = 4), normal CSF obtained from patients with noninflammatory CSF conditions (n = 9), and polyclonal rabbit IgG (n = 7), were combined for the analysis. There was a total of 12 brief nonconvulsive seizures in 5 of 20 control mice. Specifically, 2, 4, and 6 seizures were recorded in mice treated with vehicle, rabbit IgG, or control CSF, respectively ( Figure 2 A-C). There were no significant differences in the number of seizures among the 3 control groups (P = 0.54, Kruskal-Wallis test).
The median number of seizures recorded during the 2-week period in mice treated with rabbit anti-NMDAR IgG and patient CSF was 13 (interquartile range [IQR] 8-33) and 39 (IQR 10-157), respectively. The median number of seizures in the combined control group was 0 (IQR 0-1). As expected, the median seizure counts were significantly higher in mice treated with rabbit anti-NMDAR IgG and patient CSF compared to the control (P = 0.0006 and P < 0.0001 vs control, respectively; Dunn tests).
The median total time in seizures over the 2-week period in the combined control, rabbit anti-NMDAR IgG, and patient CSF-treated groups (median and IQR) were 0 (0-0.24), 29.8 (10.2-47.9), and 75.6 (13.3-358) minutes, respectively ( Figure 2B ). Mice treated with NMDAR antibody and patients' CSF spend more time in seizures compared to the control mice (P < 0.0001, Kruskal-Wallis test; P = 0.0005 and P < 0.0001, Dunn tests). The latencies to first seizure (mean ± SEM) in mice infused with anti-NMDAR IgG solution and patient CSF were not different from those in control mice (66.4 ± 28.1; 50.4 ± 17.3, and 46 ± 20.1 hours, respectively (P = 0.78; ANOVA; data not shown).
Ninety-three percent of seizures recorded in mice treated with antibodies or patient CSF were exclusively electrographic and 2% of seizures were accompanied by only minimal behavioral changes corresponding to the modified Racine's scores 1-3 27 ( Figure 2C and Video S1). More severe seizures characterized by isolated myoclonic jerks and sustained clonic activity (scores 4 and 5, respectively) occurred in a few animals and constituted 5% of all seizures in these mice. The few seizures in the combined control infusion group were all nonconvulsive ( Figure 2C ). The median seizure duration in mice treated with CSF from patients with anti-NMDAR encephalitis was 62.4 seconds (IQR 8.97-434) seconds ( Figure 2D ). Consistent with the effects of the whole CSF from the affected patients, patient IgG purified from anti-NMDAR antibody-containing CSF also induced seizures in mice (median 35 in 2 weeks; IQR 0-139; P = 0.02; Mann-Whitney test vs combined control; Figure 2E ). Seizures occurred in 6 of 8 mice, and the median time spent in seizures over the 2-week period was 66.7 (2.7-292.2) minutes (data not shown). 
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There was a total of 6 nonconvulsive seizures in 4 of 9 animals from the combined control group (median 0, IQR 0-1.5) comprising mice treated with normal human CSF (n = 3), human albumin (n = 3), and normal human serum IgG (n = 3). There were no significant differences between the number of seizures in the latter subgroups (P = 0.89, Kruskal-Wallis test). The total time spent in seizures in the patient IgG-treated group was significantly longer than that in the control (P = 0.02, Mann-Whitney test). In parallel to seizure presentation in mice treated with whole CSF from affected patients, 95% of seizures in mice were exclusively electrographic (data not shown). The latencies to first seizure (mean ± SEM) in mice infused with patient anti-NMDAR containing IgG were not different from those in control mice (118.6 ± 47.1 and 36.9 ± 26.7 hours, respectively; P = 0.15; t test, data not shown).
The majority of seizures were characterized by highamplitude rhythmic spikes that occurred at relatively constant rates or at irregular intervals ( Figure 3A and Video S1). In the former pattern, the spikes occurring at relatively with patient anti-NMDAR antibodies in the IgG fraction purified from the pooled CSF (final titer 1:1024), normal human CSF, human albumin, and normal human serum IgG (blue, purple, and orange closed circles, respectively; P = 0.02). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 vs control, Dunn selected comparison test (A, B) or Mann-Whitney test (E) constant intervals had larger amplitude and duration compared to the latter, which was characterized by spikes of varied amplitude occurring at irregular intervals. The corresponding behavior varied from sleeping or normal exploratory activity or freezing and myoclonic jerks ( Figure 2C , Videos S1 and S2). A less-common seizure pattern was characterized by high-amplitude fast rhythmic activity that fluctuated in amplitude in a spindle-like fashion ( Figure 3B ). Both patterns could occur in the same animals. The seizures observed in control mice were largely characterized by rhythmic spikes occurring with constant frequency.
We also performed whole cell patch recordings from CA1 pyramidal neurons in hippocampal slices prepared from control and anti-NMDAR-positive CSF-treated animals. The resting membrane potential, amplitude, and frequency of spontaneous excitatory postsynaptic currents (EPSCs) and inhibitory postsynaptic currents (IPSCs) were similar in the 2 treatment groups. The input resistance and response to depolarizing current injection were reduced in cells from the antibody-infused animals (P = 0.02 and P = 0.002, respectively, unpaired and paired t tests, respectively; Figure S2 in Data S1).
| Antibody-induced seizure timing does not demonstrate daily or diurnal fluctuations
To determine the temporal distribution of seizure burden (ie, total number of seizures) during the continuous exposure to patients' CSF, the temporal fluctuation of seizure occurrence was assessed in mice with high (>39) and low (≤39, split was based on the median seizure count) seizure burden over the 2-week period (8 mice in each group; Figure 4A ). As expected, the mean daily seizure scores were significantly higher in mice with high seizure burden compared to those with low seizure burden (group effect: P = 0.047; 2-way ANOVA). The seizure scores in the high seizure burden group were higher on days 11-15 but not on days 1-5 and 6-10 (P = 0.02, P = 0.32, and P = 0.99, respectively; Sidak multiple comparison tests). The triaging of mice into groups with low or high seizure burden over the first week, and the seizure score on days 11-15, can together be applied to determine the response to treatment for seizures in future interventional studies.
To determine if seizure timing exhibits a diurnal pattern, seizure burden within the light and dark cycles was examined by pooling all seizures recorded in 2 weeks in 8 CSFadministered mice with high seizure density in successive 2-hour intervals ( Figure 4C ). The data indicate that only minimal diurnal variations occurred in the seizure count (F 3.1; 21.5 = 1.17, P = 0.34; repeated-measures ANOVA), and the total median seizure counts during the light and dark cycles were not different (P = 0.72, t test; Figure 4D ).
To determine whether seizures tended to occur in clusters (cf. Ref. Figure 4B ). Because evenly spaced seizures would have occurred every 190 minutes, this analysis provides strong evidence for seizure clustering in this mouse model (P < 0.0001 for measured ISI compared to expected ISI of 190 minutes, one sample t test). Indeed, fewer than 4% of all seizures had an ISI >190 minutes, whereas >20% of seizures occurred with an ISI of <1 minute.
| Anti-NMDAR antibodies did not alter behavior in mice
In the novel object test, the recognition scores (mean ± SEM) in the combined control, anti-NMDAR IgG, and patient CSF-treated mice were 0.60 ± 0.05, 0.55 ± 0.06, and 0.51 ± 0.05, respectively ( Figure 5A ). Seven of 20, 3 of 11, and 5 of 17 mice were excluded from the above groups, respectively, because these mice failed to spend more than 4.5 seconds in total exploration. The recognition scores in the control group were similar to those previously reported by other authors 31 and recorded in our laboratory.
However, we note that although the control group of mice tended to exhibit a bias in favor of the novel stimulus, this trend did not reach statistical significance (P = 0.09; onesample t test). The antibody-and patient CSF-treated mice spent equal time exploring the novel and familiar objects (P = 0.46 and P = 0.9, respectively; one-sample t tests comparing with the recognition score of 0.5); however, there were no differences in the novel object recognition scores among 3 treatment groups (F 2,30 = 0.92; P = 0.41; ANOVA). These findings fail to provide evidence that nonspatial learning and memory are affected in a novel object paradigm shortly after a 2-week infusion of antibodies. When exposed to the open field, the total distance traversed by mice (mean ± SEM) in the combined control, IgG, and patient-CSF-treated groups were 53.1 ± 4.8, 59.7 ± 2.8, and 61.0 ± 4.4 m, respectively ( Figure 5C ). Furthermore, the proportion of time spent in the inner zone of the arena in the same groups were 16.9 ± 2.3, 14.2 ± 1.4, and 12.8 ± 1.7 percent, respectively ( Figure 5B ). The locomotor and anxiety scores in the control group in our study were comparable to those previously reported in similar experimental paradigms. 32, 33 Consistent with the findings by other authors, 21 anti-NMDAR antibodies did not affect the locomotor activity and emotion-related behavior in mice (F 2,44 = 1, P = 0.36; and F 2,44 = 1. 19, P = 0.31, respectively; ANOVA). One control mouse treated with normal rabbit IgG was excluded from calculations because of data loss caused by acquisition software malfunction. The mean latencies to fall from the rotarod (mean ± SEM) in the 3 groups were 30.2 ± 3.7, 22.8 ± 3.0, and 22.5 ± 1.7 seconds ( Figure 5D ). The differences among the groups did not reach statistical significance (F 2,45 = 2.18, P = 0.12; ANOVA).
| Antibody treatment induced mild glial activation but not proliferation or neuronal death in the hippocampus
Sections of CA1 region of the hippocampus stained for GFAP immunoreactivity demonstrated a characteristic pattern of immunostaining, and the glial cells had a typical morphologic appearance ( Figure 6 ). The gliotic cells in anti-NMDAR patient CSF-treated mice (Figure 6C,D) and pilocarpine-treated mice with status epilepticus (used as a positive control, Figure 6E ,F) were identified by the presence of thick tortuous processes and more intense staining as compared to the GFAP-positive cells with thin lightly-stained processes in naive mice ( Figure 6A,B) . Fluoro-Jade C staining for degenerating neurons did not demonstrate any signs of neurodegeneration in the CA1 region of hippocampus in mice with antibody-induced or pilocarpine-induced seizures (data not shown). The number of GFAP-positive cells per mm 2 in mice treated with control CSF, rabbit anti-NMDAR IgG, or patient CSF was similar among the infused groups ( Figure S3 in Data S1).
There was no evidence of astrocyte proliferation in mice treated with purified anti-NMDAR IgG or patient CSF (F 2,35 = 2.51; P = 0.03; ANOVA; P = 0.51 and P = 0.1, anti-NMDAR IgG and patient CSF groups vs combined control group, respectively; Dunnett multiple comparison tests). Although visually the astrocyte staining appeared darker in mice infused with patient CSF (Figure 6 ), variability in the background intensity precluded quantification of this impression.
| DISCUSSION
This study demonstrates that antibodies to NMDARs can cause spontaneously occurring electrographic seizures. Similar to the patients with anti-NMDAR encephalitis, 80%-82% of whom develop seizures, 5,7 75%-93% of antibody-infused mice in the present study developed seizures. By comparison, only a few seizures were observed in control mice. Mice receiving CSF with high seizure burden could be enrolled in trials that test the response to novel anticonvulsant treatments, and daily seizure score could be used to follow these effects.
Since the initial description of anti-NMDAR encephalitis in a patient with sudden reversible psychosis, 34 major efforts have been exerted to establish the role of autoantibodies in the pathophysiology of the encephalitis phenotype, including seizures. Given that spontaneous or treatment-induced removal of the antibodies in patients with anti-NMDAR encephalitis leads to improvement in confusion, psychosis, and seizures, the antibodies were assumed to be responsible for the development of these symptoms. 4, 25, 35 Whereas seizures in anti-NMDAR encephalitis rarely persist into the late convalescent period, 7 they are present in the majority of patients during the acute phase and fail to respond to conventional antiepileptic treatments in 15%-45% of patients. 7, 14 The anti-NMDAR antibodies found in some patients with encephalitis bind to an epitope spanning amino acid residues 144-156 in the N-terminal domain of the GluN1 subunit, 4,36 affect synaptic trafficking of the adjacent GluN2A and 2B subunits, and cause internalization of NMDAR clusters. 22, 37, 38 Although the antibody-associated human memory deficits were reproduced in previous studies in rodents, spontaneous seizures were not observed in mice following a single infusion of anti-NMDAR encephalitis CSF. 18 Overt seizures were also not reported in a study with continuous icv infusion of CSF from patients with anti-NMDAR encephalitis; however, simultaneous EEG recording was not performed. 21, 38 The majority of seizures in the present study were accompanied by subtle or no motor signs; this is consistent with clinical presentation in patients with encephalitis, many of whom develop subclinical seizures and require EEG monitoring for seizure diagnosis. Exclusively electrographic seizures with spike and wave pattern are not uncommon in rodents and have been reported previously in rodent models of limbic and kainate-induced epilepsy as well as in ischemic-hypoxic seizures. 26, 39, 40 Minimal behavioral changes (eg, freezing) or lack of motor signs occur because seizures likely occur in discrete cortical regions and do not propagate to the areas responsible for motor control. In the present study, seizures caused by commercial polyclonal NMDAR IgG were similar to those produced by encephalitis-patient CSF and the purified IgG fraction from patient CSF, suggesting that seizures were directly caused by the effects of antibodies rather than being induced by other constituents of patients CSF (eg, proinflammatory cytokines) that could also promote the development of seizures. 41, 42 Furthermore, these findings indicate that exposure to antibodies must be sustained to induce seizures and that detection of seizures requires electrographic monitoring. The pathophysiology of seizures as a consequence of NMDAR dysfunction appears to be more complex than their cellular dysfunction would suggest. 43 A genetically induced ablation of the GluN1 subunit of NMDARs in γ-aminobutyric acid (GABA)ergic corticolimbic neurons of mice resulted in memory loss and anxiety, 44 a phenotype similar to that observed in rodents infused with CSF from encephalitis patients, 21 suggesting that seizure behavior might also be similarly induced by cell-specific NMDAR hypofunction in encephalitis. Recent studies showing markedly enhanced excitability of the motor cortex in rodents treated with patients' anti-NMDAR antibodies provide an early insight into the mechanisms of seizures related to NMDAR dysfunction. 45, 46 Specifically, these results supported a direct role of anti-NMDAR antibodies from encephalitis patients in altering glutamatergic neurotransmission. 46 Furthermore, excessive glutamate release in the hippocampi of rats was reported following a single intracerebral administration of anti-NMDAR encephalitis CSF, 46 supporting the concept that patients' antibodies may contribute to the removal of inhibitory tone and excessive pyramidal cell firing. Although extracellular glutamate was not measured in the present study, continuous infusion of antibody-positive CSF could induce heightened glutamate release in the hippocampus. Thus, seizures may develop in the setting of elevated extracellular glutamate if the impact of antibody-induced NMDAR hypofunction preferentially affects inhibitory interneurons. 47 However, no functional evidence of interneuronal NMDAR hypofunction has been reported (see also Figure S2 ). The decrease in inhibitory synapse density onto excitatory hippocampal neurons was found in culture after acute exposure to patients' CSF. 23 The prolonged exposure to antibodies may lead to similar adaptations at the circuit level. 16, 48 Thus, the psychosis manifesting in patients with anti-NMDAR encephalitis might be caused by the NMDAR hypofunction on inhibitory interneurons and the resultant disinhibition of cortical glutamatergic and dopaminergic projections. 48 Although the locus of seizure onset cannot be determined precisely without EEG recordings from a panel of depth and surface electrodes, the seizures detected over the parietal cortex in the present study could emanate from the hippocampus, immediately inferior to the parietal cortex. Hippocampi of mice that completed a 2-week icv infusion of patients' CSF had the highest density of the brain-bound NMDAR IgGs and the most robust decrease of NMDAR clusters. 21 Paradoxically, in recordings from hippocampal slices isolated from rats injected intracerebrally with anti-NMDAR encephalitis CSF, the action potential threshold of hippocampal pyramidal neurons was higher than that in controls treated with normal CSF. 18 Consistent with that, we found that excitability and membrane resistance of granule cells in slices of mice treated with patient CSF were reduced compared to those in control mice (Figure S2 ). Further studies are needed to determine if the lowered excitability is homeostatically responsive to the recurrent seizures or is directly mediated by the effects of patients' autoantibodies. In mouse hippocampal slices, CSF positive for anti-NMDAR antibodies impaired LTP. 24 In addition, both short-term and prolonged administration of patients' CSF to rodents 38 led to the impairment of memory and learning. 18 In the present study, mice treated with commercial antibodies or patient CSF failed to discriminate between the novel and familiar objects based on one-sample t tests, which is consistent with memory impairment and encephalitis phenotype. However, because a strong preference for the novel object was not observed in control mice, the present assay was likely not sufficiently sensitive to assess nonspatial memory in this model. Another possibility for the lack of expected response in the control animals was an iatrogenic consequence of extensive cranial surgery. The lack of memory impairment was consistent with the previous findings 49 and could have been due to testing prior to the peak worsening. 21 Alternatively, the novel object paradigm applied in our study was not sensitive enough to reveal the differences between the 3 treatment groups in the setting of additional cerebral instrumentation. Additional tests to demonstrate antibody-induced alteration of memory in mice may need to be applied to better characterize the impairment in multiple domains of memory function. The lack of anxiety-related behavior and unaltered locomotor activity in antibody-treated mice in the present study agreed with previous reports. 21 Taken collectively, these findings suggest that a single animal model may not be suitable to reproduce various clinical symptoms of anti-NMDAR encephalitis (eg, memory loss, seizures, and dyskinesia). The neuropathology of anti-NMDAR encephalitis in autopsy specimens of affected patients and in brain tissue sections of rodents treated with patients' CSF involves deposition of IgG in the hippocampus and cortex without evidence of destruction of the nerve cells or synapses. 47 The absence of evidence for neuronal death in the hippocampi of mice in this study is therefore consistent with the previous studies. Also consistent with previous reports of astrocytic hypertrophy in seizures, 50 we observed morphologic changes in hippocampal astrocytes of mice infused with purified IgG or patients' CSF; however, we found no evidence of astrocytic proliferation in these animals. Such a dissociation between the qualitative and quantitative changes in astrocytes following seizures was reported previously in cortical neurons of mice with kainate-induced status epilepticus.
51
A limitation of the present study includes the lack of clinical information on all but one patient from whom the CSF was derived, thus restricting more complete translation of findings to the bedside. Given the very high titer of anti-NMDAR antibodies in the CSF from individual patients and that of the final pool of purified IgG (1:1024), the specimens were likely obtained before the initiation of treatment. These patients likely had severe encephalitis; however, it is unclear whether they had developed overt seizures. Another limitation stems from the constraints of the EEG recording in mice; it is challenging to fully distinguish between behavior-related EEG artifacts and rhythmic seizure patterns. Thus, the number of seizures and the severity of epileptic phenotype in mice could be underestimated. Furthermore, rhythmic patterns appearing only in a single EEG lead were excluded; thus, some focal seizures were uncounted. Future recordings from depth electrodes in targeted brain regions or the use of a wireless EEG system may reduce movement-related artifacts. The CSF from patients with noninflammatory CNS conditions used as a control in our study was previously validated in other animal models of autoimmune encephalitis and related in vitro TARASCHENKO ET AL.
| 461 studies. 21, 22 An additional control group of mice with the CSF from affected patients but having anti-GluN1 antibodies removed by means of immunodepletion can be used in future experiments.
In conclusion, this study provides the first demonstration of the pathogenicity of neuronal antibodies for seizures in autoimmune encephalitis. The mouse model developed herein can be applied to test novel pharmacologic treatments for refractory autoimmune seizures. This model can also be used to study the etiology of seizures in autoimmune epilepsy, examining CSF itself in comparison with other potentially pathogenic components. Furthermore, this study provides a foundation for future in-depth examination of the effects of antibodies on extended hippocampal circuitry that could elucidate new targets for therapeutic neurostimulation in autoimmune epilepsy.
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